Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + penpulimab for resectable locally advanced esophageal squamous cell carcinoma
ChiCTR2200064848Phase 2Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Oct 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and penpulimab in Esophageal Squamous Cell Carcinoma (ESCC) and esophageal cancer, sponsored by West China Hospital of Sichuan University. Primary endpoint: Pathologic complete response rate. Started Oct 2022; status: completed.
02
Drugs
anlotinibpenpulimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)esophageal cancer
Beyond the preview
Go deeper on ChiCTR2200064848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064848.